A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.

By J. Calabrese, P. Keck, W. Macfadden, M. Minkwitz, T. Ketter, R. Weisler, A. Cutler, R. McCoy, E. Wilson, J. Mullen. American Journal of Psychiatry, 2005

778 citations recorded by the source corpus.

Subfields: Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/0b9fba3cb3bd531dc502a083c4943503f09e56a9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

1. Sidney H. Kennedy
2. Marcus Munafò
3. Oliver D. Howes

In Psychiatry and Mental health

1. Marcus Munafò
2. L. Yatham
3. Oliver D. Howes

Citations in the corpus

• Evidence-based guidelines for treating bipolar disorder: revised third edition Recommendations from the British Association for Psychopharmacology (2009, positive): “At doses of 300 and 600 mg/day it produced large and early attenuation of depressive symptoms in bipolar patients compared with placebo (Calabrese et al., 2005; Thase et al., 2006).”
• Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. (2013, background): “The four large RCTs demonstrating the efficacy of quetiapine monotherapy in combined groups of patients with BD I or BD II depression, which were cited in previous iterations of these guidelines, have now all been published: BOLDER I (88) and II (89), and EMBOLDEN I (90) and EMBOLDEN II (91).”
• Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders (2015, background): “Randomised controlled trials report that olanzapine (Tohen et al., 2003c, 2012), quetiapine (Calabrese et al., 2005b; McElroy et al., 2010; Thase, 2006; Young et al., 2010) and lurasidone (Loebel et al., 2014a, 2014b) are effective treatments for bipolar depression, but these studies have…”
• A Randomized Add-on Trial of an N-methyl-d-aspartate Antagonist in Treatment-Resistant Bipolar Depression (2010, neutral): “Lithium 7 (39) 16 (89) Antidepressants Duloxetine 7 (39) 13 (72) SSRI 6 (33) 18 (100) Bupropion 5 (28) 16 (89) Venlafaxine 2 (11) 11 (61) Trazodone 2 (11) 7 (39) MAOI 1 (6) 7 (39) TCA 0 7 (39) Mirtazapine 0 6 (33) Nefazodone 0 3 (17) Antipsychotics Quetiapine 9 (50) 16 (89) Aripiprazole 2 (11) 10 (5”
• Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. (2009, background): “There are now four large RCTs demonstrating the efficacy of quetiapine monotherapy in bipolar depression; BOLDER I (62) and II (63), which were cited in previous iterations of these guidelines; and two additional eight-week RCTs, EMBOLDEN I (64) and EMBOLDEN II (65), which have now been reported in ”